PL BioScience, a German life science company specializing in the production and development of human platelet lysate (HPL) for cell expansion, reported the first-time production of an artificial HPL cell culture solution. In partnership with the Korean biotech DewCell Biotherapeutics, the first company to generate artificial platelets from stem cells in a reactor, PL BioScience officials say company scientists developed a proprietary method to transform these lab-grown platelets into a cell culture supplement.
The new technology offers an animal-free alternative to Fetal Calf/Bovine Serum (FCS/FBS) and donor-derived, natural HPL for regenerative medicine, cell therapy, and biopharma applications, according to Hatim Hemeda, PhD, CEO of PL BioScience.
“Cell culture innovation is crucial for advancing modern medicine, drug discovery, and understanding complex biological systems,” said Hemeda. “We are proud to contribute to the field with the first, scalable artificial HPL solution that, in the mid-term, can be produced in a nearly unlimited supply to meet the growing biopharmaceutical industry needs.”
The post First-time Production of an Artificial Human Platelet Lysate appeared first on GEN - Genetic Engineering and Biotechnology News.
The new technology offers an animal-free alternative to Fetal Calf/Bovine Serum (FCS/FBS) and donor-derived, natural HPL for regenerative medicine, cell therapy, and biopharma applications, according to Hatim Hemeda, PhD, CEO of PL BioScience.
“Cell culture innovation is crucial for advancing modern medicine, drug discovery, and understanding complex biological systems,” said Hemeda. “We are proud to contribute to the field with the first, scalable artificial HPL solution that, in the mid-term, can be produced in a nearly unlimited supply to meet the growing biopharmaceutical industry needs.”
The post First-time Production of an Artificial Human Platelet Lysate appeared first on GEN - Genetic Engineering and Biotechnology News.